<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161444</url>
  </required_header>
  <id_info>
    <org_study_id>16/B/06</org_study_id>
    <secondary_id>2016-A01173-48</secondary_id>
    <nct_id>NCT03161444</nct_id>
  </id_info>
  <brief_title>Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.</brief_title>
  <acronym>ZIKAVIH</acronym>
  <official_title>Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Guadeloupe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will estimate the cumulative incidence of Zika infection at the end of the first
      epidemic in the French West Indies in a sample of patients followed for HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Zika virus infection is expanding in all tropical and subtropical areas. The presence of
      Aedes albopictus in southern France raises concerns about the occurrence of outbreaks of
      indigenous Zika virus transmission. In this context, knowledge of the cumulative impact of
      the epidemic that affected the Caribbean in 2016 is an important issue for the management of
      future epidemics and modeling work. Since the Zika virus has not yet been circulated in the
      Lesser Antilles, the cumulative incidence rate can be estimated by conducting a general
      population seroprevalence survey at the end of the epidemic, or more simply within a cohort
      of patients regularly monitored and whose habitat is distributed throughout the study area.
      Thus, HIV-infected patients who benefit from regular clinical biological monitoring
      constitute a population sample perfectly adapted to the study of the emergence of the Zika
      virus in the French West Indies. The cumulative incidence of infection with the chikungunya
      virus after the 2014 epidemic has thus been estimated at 58% for Martinique and Guadeloupe
      using this method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A blood sample collection for the study will be taken to each participant. Each subject enrolled must have previously participated in the study CHIKVIH.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or not of Zika virus-specific immunoglobulin G antibodies in the serum taken after the epidemic</measure>
    <time_frame>1 day</time_frame>
    <description>Presence or absence of ZIKV-specific IgG antibodies in the serum taken at the end of the Zika epidemic within six months of the official end of the epidemic for each territory of the French west Indies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Existence or not of clinical signs evocating of an episode of disease with Zika virus.</measure>
    <time_frame>1 day during the study</time_frame>
    <description>The clinician in charge of the patient will question him about the occurrence of a clinical episode suggestive of Zika virus infection during the epidemic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or not of Dengue virus specific antibodies before the outbreak of Zika virus infection, sought on the samples taken at the end of the chikungunya epidemic.</measure>
    <time_frame>1 day on biological sample collected before the outbreak of Zika virus</time_frame>
    <description>Serological analysis will be performed on biological sample collected in the frame of the heath follow-up of teh patient and stored before the epidemic of Zika Virus disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or not of Chikungunya-specific antibodies before the outbreak of Zika virus infection, sought after sampling at the end of the chikungunya epidemic.</measure>
    <time_frame>1 day on biological sample collected before the outbreak of Zika virus</time_frame>
    <description>Serological analysis will be performed on biological sample collected in the frame of the heath follow-up of teh patient and stored before the epidemic of Zika Virus disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the CD4 lymphocyte levels before and after the outbreak of Zika virus</measure>
    <time_frame>6 months before the outbreak of Zika virus ; 12 months of the outbreak of Zika virus; First 6 months after the outbreak of Zika virus</time_frame>
    <description>All biological results for CD4 Lymphocyte will be collected retrospectivelly : 6 months before the outbreak of Zika virus , 12 months of the outbreak of Zika virus and 6 months after the outbreak of Zika virus in order to observe its evolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the HIV1 RNA levels before and after the outbreak of Zika virus</measure>
    <time_frame>6 months before the outbreak of Zika virus ; 12 months of the outbreak of Zika virus; First 6 months after the outbreak of Zika virus</time_frame>
    <description>All biological results for HIV1 RNA will be collected retrospectivelly : 6 months before the outbreak of Zika virus , 12 months of the outbreak of Zika virus and 6 months after the outbreak of Zika virus in order to observe its evolution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>HIV Infections</condition>
  <condition>Zika Virus Infection</condition>
  <arm_group>
    <arm_group_label>Elective patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological sample collection</intervention_name>
    <description>A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.</description>
    <arm_group_label>Elective patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 18 years pold)

          -  Followed for HIV infection at the 2 investigators centers (1 located at Martinique and
             1 at Guadeloupe)

          -  Resident in Martinique /Guadeloupe (French West Indies) betwwen 01JAN2016 and
             31DEC2016

          -  Affiliate or beneficiary of a social security scheme.

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Patient who has stayed in another area at risk of transmission of the Zika virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre CABIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Martinique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno HOEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Gaudeloupe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andre CABIE, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Martinique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janick JEAN-MARIE, Master</last_name>
    <phone>0596 59 26 97</phone>
    <phone_ext>+596</phone_ext>
    <email>janick.jean-marie@chu-martinique.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle CALMONT, Master</last_name>
    <phone>0596 59 26 97</phone>
    <phone_ext>+596</phone_ext>
    <email>isabelle.calmont@chu-martinique.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janick JEAN-MARIE, Master</last_name>
      <phone>0596 59 26 97</phone>
      <phone_ext>+596</phone_ext>
      <email>janick.jean-marie@chu-martinique.fr</email>
    </contact>
    <contact_backup>
      <last_name>isabelle CALMONT, Master</last_name>
      <phone>0596 59 26 97</phone>
      <phone_ext>+596</phone_ext>
      <email>isabelle.calmont@chu-martinique.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Andre CABIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Guadeloupe</name>
      <address>
        <city>Pointe-Ã -Pitre</city>
        <zip>97159</zip>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvire Couchy, Master</last_name>
      <phone>0590 91 19 30</phone>
      <phone_ext>+590</phone_ext>
      <email>elvire.couchy@chu-guadeloupe.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno HOEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Guadeloupe</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

